Pharmacists suffered from inventory after six products, including Diovan and Exforge, by Novartis Korea, were announced to local pharmacies on the afternoon of the 1st. When there were concerns that impurities were detected, Novartis Korea explained that the quality was fine, but it was a lot release that was decided due to administrative delays.

According to local pharmacies on the 1st, four products including Diovan, Co-Diovan, Exforge, and Entresto by Novartis Korea and Kotarec and Tarec by Sandoz Korea will be suspended from September. It said the lot release was suspended because it did not submit safety inspection data to the MFDS until the end of August. Upon hearing the news, pharmacists rushed